GlassScriptPhysician profile
Robert S Thacker
NPI 1124309224
$681.33
in general payments reported to CMS, 2019-2025
15 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.01 · 2022: $82.31 · 2023: $138 · 2024: $62.61 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334 · Consulting Fee: $150 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.02 |
| Consulting Fee | $150.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $150.00 | 2025 | |
| Janssen Pharmaceuticals, INC | $127.04 | 2023-2024 | Invega Sustenna |
| Novo Nordisk INC | $91.03 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $49.99 | 2023-2024 | Veozah |
| Dexcom, INC. | $49.37 | 2021-2022 | |
| Abbvie INC. | $31.73 | 2022 | |
| Biogen, INC. | $25.51 | 2025 | Zurzuvae |
| Tandem Diabetes Care, INC. | $23.93 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Vanda Pharmaceuticals INC. | $23.34 | 2025 | Fanapt |
| Alkermes, INC. | $20.87 | 2025 | Aristada, Aristada Initio |
| Exeltis, USA INC. | $20.73 | 2025 | Slynd |
| Pfizer INC. | $18.89 | 2025 | |
| Viatris Specialty LLC | $18.43 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $16.22 | 2022 | |
| Amgen INC. | $14.25 | 2025 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Thacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.